Company intelligence / Profile preview

Escend Pharmaceuticals, Inc.

Menlo Park, California, United Statesescendpharma.com ↗

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Escend's lead drug ES-3000 received FDA IND clearance in July 2022 for a Phase I study in relapsed or refractory acute myeloid leukemia. The drug has orphan designation for AML and CML. The company is also preparing for a Phase I/II platform study for MDS.

Therapeutic areas: OncologyHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ES-3000

Unknown

Beyond the preview

Go deeper on Escend Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Escend Pharmaceuticals, Inc..

Explore the full profile